XML 89 R152.htm IDEA: XBRL DOCUMENT v3.20.1
Non-Controlling Interests - Movement (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disclosure of subsidiaries [line items]      
Balance at beginning of the year € 4,696,604 € 3,633,965 € 3,727,978
Profit/(loss) for the year 648,644 594,406 661,314
Balance at end of the year 6,845,768 4,696,604 3,633,965
Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year 471,050 4,886 6,497
Profit/(loss) for the year 23,498 (2,236) (1,386)
Additions   (2,236)  
Additions 1,534,045    
Disposals (9) (914)  
Business combinations/ Additions to consolidated Group   469,881  
Capital increases 6,642    
Translation differences 11,921 (567)  
Balance at end of the year 2,023,649 471,050 4,886
Grifols (Thailand) Ltd | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year 3,935 3,579  
Profit/(loss) for the year 193 193  
Disposals   (43)  
Translation differences 421 206  
Balance at end of the year 4,549 3,935 3,579
Grifols Malaysia Sdn Bhd | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year 1,735 1,372  
Profit/(loss) for the year 380 326  
Translation differences 56 37  
Balance at end of the year 2,171 1,735 1,372
Araclon Biotech, S.A | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year (3,488) (1,477)  
Profit/(loss) for the year (1,975) (2,011)  
Capital increases 5,892    
Balance at end of the year 429 (3,488) (1,477)
Progenika Biopharma, S.A. | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year 9 880  
Profit/(loss) for the year 0    
Disposals (9) (871)  
Balance at end of the year   9 880
VCN Bioscience, S.L. | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year 140 421  
Profit/(loss) for the year (292) (281)  
Balance at end of the year (152) 140 421
Kiro Grifols , S.L. | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year (352) 111  
Profit/(loss) for the year (374) (463)  
Capital increases 750    
Balance at end of the year 24 (352) € 111
Haema, AG | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year 220,190    
Profit/(loss) for the year 5,881    
Business combinations/ Additions to consolidated Group   220,190  
Balance at end of the year 226,071 220,190  
Biotest US Corporation | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Balance at beginning of the year 248,881    
Profit/(loss) for the year 19,685    
Business combinations/ Additions to consolidated Group   249,691  
Translation differences 11,444 (810)  
Balance at end of the year 280,010 € 248,881  
Grifols Diagnostic Solutions, Inc. | Non-controlling interests      
Disclosure of subsidiaries [line items]      
Additions 1,510,547    
Balance at end of the year € 1,510,547